

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<p>1. Name and Address of Reporting Person*</p> <p><u>G1 EXECUTION SERVICES, LLC</u></p> <hr/> <p>(Last) (First) (Middle)</p> <p>175 W. JACKSON BLVD., SUITE 1700</p> <p>501 PLAZA 2</p> <hr/> <p>(Street)</p> <p>CHICAGO IL 60604</p> <hr/> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement (Month/Day/Year)</p> <p>01/27/2020</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p><u>ACHILLION PHARMACEUTICALS INC [ACHN]</u></p> <hr/> <p>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</p> <p>Director <input checked="" type="checkbox"/> 10% Owner</p> <p>Officer (give title below) Other (specify below)</p>	<p>5. If Amendment, Date of Original Filed (Month/Day/Year)</p> <hr/> <p>6. Individual or Joint/Group Filing (Check Applicable Line)</p> <p>Form filed by One Reporting Person</p> <p><input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p>
--	--	--	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,917	D ⁽¹⁾⁽³⁾	
Common Stock	14,115,498	D ⁽²⁾⁽³⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Call Option (right to buy)	(4)	12/18/2020	Common Stock	454,900	7	D ⁽²⁾⁽³⁾	
Total Return Swap ⁽⁵⁾	(6)	07/29/2020	Common Stock	8,000	(5)	D ⁽³⁾	
Total Return Swap ⁽⁵⁾	(6)	07/30/2020	Common Stock	8,000	(5)	D ⁽³⁾	
Total Return Swap ⁽⁵⁾	(6)	07/31/2020	Common Stock	8,000	(5)	D ⁽³⁾	
Total Return Swap ⁽⁵⁾	(6)	08/03/2020	Common Stock	7,100	(5)	D ⁽³⁾	

1. Name and Address of Reporting Person*

G1 EXECUTION SERVICES, LLC

(Last) (First) (Middle)

175 W. JACKSON BLVD., SUITE 1700

501 PLAZA 2

(Street)

CHICAGO IL 60604

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC

(Last) (First) (Middle)

401 CITY AVENUE, SUITE 220

(Street)

BALA CYNWYD PA 19004

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SUSQUEHANNA SECURITIES, LLC

(Last) (First) (Middle)

401 CITY AVENUE, SUITE 220

(Street)

BALA CYNWYD PA 19004

(City)

(State)

(Zip)

Explanation of Responses:

1. These securities are directly owned by G1 Execution Services, LLC ("G1X").
2. These securities are directly owned by Susquehanna Securities, LLC ("SS").
3. G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
4. These options are exercisable at any time prior to their expiration.
5. SFNDI has entered into cash-settled total return swaps with an unaffiliated third party financial institution, under which SFNDI acquired an aggregate of 31,100 "notional" shares of Achillion Pharmaceuticals, Inc. ("Achillion") common stock at prices ranging from \$2.12 to \$2.24 per share. The swap agreements provide that, upon settlement of the swaps, SFNDI will pay the applicable purchase price to the counterparty, and the counterparty will pay to SFNDI an amount equal to the then market price of the applicable number of shares of Achillion common stock. These swaps provide SFNDI with economic results that are comparable to the economic results of ownership of, but do not provide SFNDI with the power to vote or direct the voting of, or dispose of or direct the disposition of, the shares of common stock that are the subject of such swap.
6. Each of these total return swaps may be settled at any time prior to its expiration in SFNDI's discretion.

G1 Execution Services, LLC

By: /s/ Brian Sopinsky Name: 01/30/2020

Brian Sopinsky Title: Secretary

Susquehanna Fundamental

Investments, LLC By: /s/ Brian

Sopinsky Name: Brian 01/30/2020

Sopinsky Title: Assistant

Secretary

Susquehanna Securities, LLC

By: /s/ Brian Sopinsky Name: 01/30/2020

Brian Sopinsky Title: Secretary

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.